Previous Close | 2,275.50 |
Open | 2,313.00 |
Bid | 2,264.00 x 0 |
Ask | 2,268.00 x 0 |
Day's Range | 2,261.50 - 2,321.50 |
52 Week Range | 2,175.00 - 3,198.00 |
Volume | |
Avg. Volume | 4,683,053 |
Market Cap | 2.858T |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | 20.85 |
EPS (TTM) | 108.77 |
Earnings Date | May 09, 2023 - May 15, 2023 |
Forward Dividend & Yield | 32.00 (1.41%) |
Ex-Dividend Date | Mar 30, 2023 |
1y Target Est | 3,423.30 |
Subscribe to Yahoo Finance Plus to view Fair Value for 7733.T
Olympus announced today the availability of several Experience Papers focused on the benefits of advancements in electrosurgical devices. Important to the broad range of minimally invasive surgical solutions available to patients, electrosurgical or "energy" devices are designed to allow for efficient dissection and cauterization of tissue. Many times, as explained in these papers, they also contribute to improved workflow in the procedure room. Among these papers developed for a healthcare prof
(Bloomberg) -- Bain Capital is exploring options for Works Human Intelligence Co. including a potential sale that could value the human resources software developer at as much as $2 billion, according to people familiar with the matter.Most Read from BloombergUS Inflation Tops Forecasts, Cementing Odds of Big Fed HikeTerra Co-Founder Do Kwon Faces Arrest Warrant in South KoreaStocks Hold Gains in Volatile Day After Selloff: Markets WrapUgly Selloff Pushes Stocks Down Most Since 2020: Markets Wra
Rating Action: Moody's affirms Olympus' Baa2 ratings, revises outlook to positiveGlobal Credit Research - 31 Aug 2022Tokyo, August 31, 2022 -- Moody's Japan K.K. has affirmed Olympus Corporation's (Olympus) Baa2 issuer and senior unsecured ratings. At the same time, Moody's has revised the outlook to positive from stable.Today's rating action follows Olympus' decision to divest its entire stake in a wholly-owned subsidiary Evident Corporation, which represents the scientific solutions segment, as announced on 29 August 2022 [1]. Olympus has entered into an agreement to sell this non-core business for approximately JPY430 billion to a company indirectly owned by funds advised by Bain Capital Private Equity, LP.